1609289-02-2

Upstream product

• 100-39-0 benzyl bromide 
• 125036-88-6 4-(benzyloxy)-3,5-difluorobenzaldehyde 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 
• 28177-48-2 2,6-difluorophenol 
• 118276-06-5 3,5-difluoro-4-hydroxybenzaldehyde 

Downstream Products

• 1224103-65-4 2-(4-benzyloxy-3,5-difluorophenyl)cyclopropanecarboxylic acid ethyl ester 
• 1224103-64-3 2-(3,5-difluoro-4-hydroxyphenyl)cyclopropanecarboxylic acid ethyl ester 
• 1609290-31-4 3-[3,5-difluoro-4-(2-isopropylsulfanylpyridin-3-ylmethoxy)phenyl]propionic acid ethyl ester 
• 1609286-92-1 3-[3,5-difluoro-4-(2-isopropylsulfanylpyridin-3-ylmethoxy)phenyl]propionic acid 
• 1609290-41-6 3-[3,5-difluoro-4-(2-isopropylsulfanylpyrimidin-4-ylmethoxy)phenyl]propionic acid ethyl ester 

Relevant academic research and scientific papers

THIOARYL DERIVATIVES AS GPR120 AGONISTS

The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.